The role of glutamate on the action of antidepressants

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1558-1568

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

GABA; Glia; Glutamate; Glutamine; Neuron

Indexed keywords

1 AMINOCYLO PENTANE 1,3,4 TRICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 4 PHOSPHONOPHENYLGLYCINE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACPT 1; ALPHA CYCLOPROPYL 4 PHOSPHONOPHENYLGLYCINE; AMN 081; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; DIZOCILPINE; DOPAMINE; FLUOXETINE; GLUTAMIC ACID; KAINIC ACID RECEPTOR; KETAMINE; MEMANTINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N,N' DIBENZYLHYDRYL ETHANE 1,2 DIAMINE; NORADRENALIN; PHENCYCLIDINE; RILUZOLE; SEROTONIN; TRAXOPRODIL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALZHEIMER DISEASE; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; ARTICLE; BEHAVIORAL STRESS; BINDING COMPETITION; CELL COMMUNICATION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GLIA CELL; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NEUROBIOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; POSTSYNAPTIC POTENTIAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR UPREGULATION; SCHIZOPHRENIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GLUTAMIC ACID; HUMANS; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 78650369966     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.06.013     Document Type: Article

References (156)

1. Alt A., Nisenbaum E.S., Bleakman D., Witkin J.M. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006, 71:1273-1288.
2. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., Zamberian F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731-1733.
3. Ampuero E, Rubio FJ, Falcon R, Sandoval M, Diaz-Veliz G, Gonzalez RE, Earle N, Dagnino-Subiabre A, Aboitiz F, Orrego F, Wyneken U. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 2010;169:98-108.
4. Auer D.P., Pütz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000, 47:305-313.
5. Bagley J., Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997, 77:65-73.
6. Barch D.M. Neuropsychological abnormalities in schizophrenia and major mood disorders: similarities and differences. Curr Psychiatry Rep 2009, 11:313-319.
7. Belmaker R.H., Agam G. Major depressive disorder. N Eng J Med 2008, 358:55-68.
8. Belozertseva I.V., Kos T., Popik P., Danysz W., Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007, 17:172-179.
9. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
10. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
11. Bleakman D., Alt A., Witkin J.M. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets 2007, 6:117-126.
12. Block W., Träber F., von Widdern O., Metten M., Schild H., Maier W., et al. Proton MR spectroscopy of the hippocampus at 3T in patients with unipolar major depressive disorder: correlates and predictors of treatment responses. Int J Neuropsychopharmacol 2009, 12:415-422.
13. Bogaert E, d'Ydewalle C, Van Den Bosch L. Glutamate excitotoxixcity and amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2010;9:297-304.
14. Bonanno G., Giambelli R., Raiteri L., Tiraboschi E., Zappettini S., Musazzi L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005, 25:3270-3279.
15. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003, 8:715.
16. Brennan B.P., Hudson J.I., Jensen J.E., McCarthy J., Roberts J.L., Prescot A.P., et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010, 35:834-846.
17. Brooks B.R. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol 2009, 65(Suppl 1):S17-S23.
18. Campbell S., Macqueen G. The role of hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004, 29:417-426.
19. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000, 75:889-907.
20. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
21. Chaki S., Okubo T., Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Patent CNS Drug Discov 2006, 1:1-27.
22. Chappell A.S., Gonzales C., Williams J., Witte M.M., Mohs R.C., Sperling R. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. Neurology 2007, 68:1008-1012.
23. Chaturvedi H.K., Chandra D., Bapna J.S. Interaction between N-methyl-d-aspartate receptor antagonists and imipramine in shock-induced depression. Indian J Exp Biol 1999, 37:952-958.
24. Cohen R.M., Weingartner H., Smallberg S.A., Pickar D., Murphy D.L. Effort and cognition in depression. Arch Gen Psychiatry 1982, 39:593-597.
25. Coric V., Milanovic S., Wasylink S., Patel P., Malison R., Krystal J.H. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003, 167:219-220.
26. Cryan J.F., Kelly P.H., Neijt H.C., Sansig G., Flor P.J., van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 2003, 17:2409-2417.
27. Deschwanden A., Karolewicz B., Feyissa A.M., Treyer V., Ametamey S.M., Johayem A., et al. Reduced metabotropic glutamate receptor 5 in major depression. Biol Psychiatry 2010, 67:190S.
28. Dillon P., Copeland J., Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003, 69:23-28.
29. Drew M.R., Hen R. Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol Disord Drug Target 2007, 6:205-218.
30. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
31. Durand D., Pampillo M., Caruso C., Lasaga M. Role of metabotropic glutamate receptors in the control of neuroendcrine function. Neuropharmacology 2008, 55:577-583.
32. Ferguson J.M., Shingleton R.N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007, 30:136-144.
33. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:70-75.
34. Feyissa A.M., Woolverton W.L., Miguel-Hidalgo J.J., Wang Z., Kyle P.B., Hasler G., et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:279-283.
35. Frye M.A., Tsai G.E., Huggins T., Coyle J.T., Post R.M. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2007, 61:162-166.
36. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991, 14:60-67.
37. Goff D.C., Lamberti J.S., Leon A.C., Green M.F., Miller A.L., Patel J., et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33:465-472.
38. Greco B., Lopez S., van der Putten H., Flor P.J., Amalric M. Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2010, 332:1064-1071.
39. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
40. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
41. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009, 9:197-204.
42. Hashimoto K. Comments to "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder". J Clin Psychopharmacol 2009, 29:411-412.
43. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:590.
44. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev 2004, 45:104-114.
45. Hashimoto K., Shimizu E., Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr Psychiatry Rev 2005, 1:151-163.
46. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 25:1310-1316.
47. Hasler G. Abnormal prefrontal glutamatergic and GABAeric systems in mood and anxiety disorders. Biol Psychiatry 2009, 65(Suppl):176S-177S.
48. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and γ-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64:193-200.
49. Hayashi T., Stahl S.M. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009, 34:137-146.
50. Hettema J.M., An S.S., Neale M.C., Bukszar J., van den Oord E.J., Kendler K.S., et al. Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Mol Psychiatry 2006, 11:752-762.
51. Hindmarch I., Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacol - Clin Exp 2010, 25:193-200.
52. Ishikawa M., Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010, 3:25-36.
53. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
54. Karasawa J., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005, 1042:92-98.
55. Karasawa J., Yoshimizu T., Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett 2006, 393:127-130.
56. Karolewicz B., Szebeni K., Stockmeier C.A., Konick L., Overholser J.C., Jurjus G., et al. Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004, 91:1057-1066.
57. Karolewicz B., Feyissa A.M., Chandran A., Legutko B., Ordway G.A., Rajkowska G., et al. Glutamate receptors expression in postmortem brain from depressed subjects. Biol Psychiatry 2009, 65(Suppl):177S.
58. Karolewicz B., Maciag D., O'Dwyer G., Stockmeier C.A., Feyissa A.M., Rajkowska G. Reduced level of glutamic acid decarboxylase-67kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol 2010, 13:411-420.
59. Kawashima N., Karasawa J., Shimazaki T., Chaki S., Okuyama S., Yasuhara A., et al. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 2005, 378:131-134.
60. Kessler R.C., Merikangas K.R., Wang P.S. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 2007, 3:137-158.
61. Kim J.S., Schmid-Burgk W., Claus D., Kornhuber H.H. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982, 232:299-304.
62. Kłak K., Pałucha A., Brański P., Sowa M., Pilc A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007, 32:169-172.
63. Kollmar R., Markovic K., Thürauf N., Schmitt H., Kornhuber J. Ketamine followed by memantine for the treatment of major depression. Aust NZ J Psychiatry 2008, 42:170.
64. Krystal J.H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 2007, 137:215-216.
65. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
66. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002, 7(Suppl. 1):S71-S80.
67. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005, 62:985-994.
68. Kudoh A., Takahara Y., Katagai H., Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002, 95:114-118.
69. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. Jama 2004, 292:2901-2908.
70. Lappalainen J., Sanacora G., Kranzler H.R., Malison R., Hibbard E.S., Price L.H., et al. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet B Neuropsychiatr Genet 2004, 124B:81-86.
71. Lavreysen H., Wouters R., Bischoff F., Nóbrega Pereira S., Langlois X., Blokland S., et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacol 2004, 47:961-972.
72. Legutko B., Szewczyk B., Pomierny-Chamioło L., Nowak G., Pilc A. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep 2006, 58:427-430.
73. Lekman M., Paddock S., McMahon F.J. Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Mol Diagn Ther 2008, 12:321-330.
74. Lesage A, Steckler T. Metabotropic glutamate mGluR1 receptor stimulation and blockade: Therapeutic opportunities in psychiatric illness. Eur J Pharmacol 2010;639:2-16.
75. Levinson D.F. The genetics of depression: a review. Biol Psychiatry 2006, 60:84-92.
76. Levine J., Panchalingam K., Rapoport A., Gershon S., McClure R.J., Pettegrew J.W. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000, 47:586-593.
77. Li X., Tizzano J.P., Griffey K., Clay M., Lindstrom T., Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
78. Li X., Need A.B., Baez M., Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006, 319:254-259.
79. Liebrenz M., Borgeat A., Lesinger R., Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007, 137:234-246.
80. Liebrenz M., Stohler R., Borgeat A. Repeated intravenous ketamine therapy in a patient with a treatment-resistant major depression. World J Biol Psychiatry 2009, 10(4 Pt 2):640-643.
81. Lowy M.T., Wittenberg L., Yamamoto B.K. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995, 65:268-274.
82. Machado-Vieira R., Salvadore G., Luckenbaugh D.A., Manji H.K., Zarate C.A. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008, 69:946-958.
83. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007, 9:467-474.
84. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
85. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998, 97:302-308.
86. Manji H., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med 2001, 7:541-547.
87. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray N., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707-742.
88. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010, 33:71-82.
89. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
90. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37:124-129.
91. Michael-Titus A.T., Bains S., Jeetle J., Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression?. Neuroscience 2000, 100:681-684.
92. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155-1158.
93. Mitsukawa K., Yamamoto R., Ofner S., Nozulak J., Pescott O., Lukic S., et al. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci USA 2005, 102:18712-18717.
94. Musazzi L., Milanese M., Farisello P., Zappettini S., Tardito D., Barbiero V.S., et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS ONE 2010, 5:e8566.
95. Navarro J.F., De Castro V., Martín-López M. JNJ16259685, a selective mGlu1 antagonist, suppresses isolation-induced aggression in male mice. Eur J Pharmacol 2008, 586:217-220.
96. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia M. Neurobiology of depression. Neuron 2002, 34:13-25.
97. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010, 50:295-322.
98. Nudmamud-Thanoi S., Reynolds G.P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004, 372:173-177.
99. O'Connor RM, Finger BC, Flor PJ, Cryan JF. Metabotropic glutamate receptor 7: At the interface of cognition and emotion. Eur J Pharmacol 2010;639:123-31.
100. Oliveira R.M., Guimarães F.S., Deakin J.F. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008, 41:333-341.
101. O'Neill M.J., Witkin J.M. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007, 8:603-620.
102. Ostroff R., Gonzales M., Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005, 162:1385-1386.
103. Paddock S., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007, 164:1181-1188.
104. Pałucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007, 115:116-147.
105. Pałucha A., Tatarczyńska E., Brański P., Szewczyk B., Wierołlska J.M., Kłak K., et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacol 2004, 46:151-159.
106. Pałucha A., Brański P., Szewczyk B., Wierołlska J.M., Kłak K., Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005, 81:901-906.
107. Pałucha A., Kłak K., Brański P., van der Putten H., Flor P.J., Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) 2007, 194:555-562.
108. Pałucha-Poniewiera A., Kłodzińska A., Stachowicz K., Tokarski K., Hess G., Schann S., et al. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 2008, 55:517-524.
109. Paslakis G., Gilles M., Meyer-Lindenberg A., Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2010, 43:33-35.
110. Paul R., Schaaff N., Padberg F., Möller H.J., Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 2009, 10:241-244.
111. Perry E.B., Cramer J.A., Cho H.S., Petrakis I.L., Karper L.P., Genovese A. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 2007, 192:253-260. Yale Ketamine Study Group.
112. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009, 65:181-184.
113. Pilc A., Kłodzińska A., Brański P., Nowak G., Pałucha A., Szewczyk B., et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacol 2002, 43:181-187.
114. Pilc A., Chaki S., Nowak G., Witkin J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008, 75:997-1006.
115. Pittenger C., Sanacora G., Krystal J.H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007, 6:101-115.
116. Porter P.J. Neurocognitive impairment in drug-free patients with major depressive disorder. Bri J Psychiatry 2003, 182:214-220.
117. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
118. Price R.B., Shungu D.C., Mao X., Nestadt P., Kelly C., Collins K.A., et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry 2009, 65:792-800.
119. Reznikov L.R., Grillo C.A., Piroli G.G., Pasumarthi R.K., Reagan L.P., Fadel J. Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. Eur J Neurosci 2007, 25:3109-3114.
120. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007, 10:1110-1115.
121. Salling M.C., Faccidomo S., Hodge C.W. Nonselective suppression of operant ethanol and sucrose self-administration by the mGluR7 positive allosteric modulator AMN082. Pharmacol Biochem Behav 2008, 91:14-20.
122. Salvadore G., Cornwell B.R., Colon-Rosario V., Coppola R., Grillon C., Zarate C.A., et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009, 65:289-295.
123. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. J Clin Psychiatry 2009, 70:1473-1474.
124. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 2. J Clin Psychiatry 2009, 70:1604-1605.
125. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., et al. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
126. Sanacora G., Kendell S.F., Levin Y., Simen A.A., Fenton L.R., Coric V., et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007, 61:822-825.
127. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
128. Schiffer H.H. Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?. Mol Neurobiol 2002, 25:191-212.
129. Sen S., Sanacora G. Major depression: emerging therapeutics. Mt Sinai J Med 2008, 75:204-225.
130. Shyn S.I., Hamilton S.P. The genetics of major depression: moving beyond the monoamine hypothesis. Psychiat Clin North Am 2010, 33:125-140.
131. Sinner B., Graf B.M. Ketamine. Handb Exp Pharmacol 2008, 182:313-333.
132. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20years on. Trends Pharmacol Sci 2009, 30:563-569.
133. Stefanczyk-Sapieha L., Oneschuk D., Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008, 11:1268-1271.
134. Suzuki G., Tsukamoto N., Fushiki H., Kawagishi A., Nakamura M., Kurihara H. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J Pharmacol Exp Ther 2007, 323:147-156.
135. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005, 4:131-144.
136. Tanti A., Belzung C. Open questions in current models of antidepressant action. Bri J Pharmacol 2010, 159:1187-1200.
137. Tatarczyńska E., Kłodzińska A., Kroczka B., Chojnacka-Wójcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 2001, 158:94-99.
138. Tatarczyńska E., Pałucha A., Szewczyk B., Chojnacka-Wójcik E., Wierołlska J., Pilc A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S, 3R, 4S)-1-aminocyclopentane-1, 3, 4-tricarboxylic acid (ACPT-I) in rats. Pol J Pharmacol 2002, 54:707-710.
139. Tokarski K., Bobula B., Wabno J., Hess G. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 2008, 153:789-795.
140. Tsai G.E. Searching for rational anti-N-methyl-d-aspartate treatment for depression. Arch Gen Psychiatry 2007, 64:1099-1100.
141. Tsunoka T., Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:875-879.
142. Valentine G.W., Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol 2009, 78:431-439.
143. Wierołlska J.M., Szewczyk B., Brański P., Pałucha A., Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002, 23:213-216.
144. Wierołlska J.M., Legutko B., Dudys D., Pilc A. Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol Rep 2008, 60:844-855.
145. Wilcock G.K. Memantine for the treatment of dementia. Lancet Neurol 2003, 2:503-505.
146. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 2007, 6:87-100.
147. Xing G., Chavko M., Zhang L.X., Yang S., Post R.M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res 2002, 58:21-30.
148. Yasuhara A., Chaki S. Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. Open Med Chem J 2010, 4:20-36.
149. Yasuhara A., Nakamura M., Sakagami K., Shimazaki T., Yoshikawa R., Chaki S., et al. Prodrugs of 3-(3, 4-dichlorobenzyloxy)-2-amino-6- fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg Med Chem 2006, 14:4193-4207.
150. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002, 71:341-344.
151. Yoshimizu T., Chaki S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 2004, 315:493-496.
152. Yoshimizu T., Shimazaki T., Ito A., Chaki S. A mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006, 186:587-593.
153. Zarate C.A., Manji H.K. Riluzole in psychiatry: a systemic review of the literature. Expert Opin Drug Metab Toxicol 2008, 4:1223-1234.
154. Zarate C.A., Payne J.L., Quiroz J., Sporn J., Denicoff K.K., Luckenbaugh D.A., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171-174.
155. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
156. Zarate C.A., Singh J.B., Quiroz J.A., De Jesus G., Genicoff K.K., Luckenbaugh D.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153-155.